Calico Life Sciences, Alphabet’s longevity-focused biotech, has secured exclusive rights outside China to Mabwell Bioscience's IL-11 targeting monoclonal antibody, 9MW3811, through a deal valued at up to $571 million, including $25 million upfront. The therapeutic, currently in Phase 1 trials in China and Australia for indications including idiopathic pulmonary fibrosis, has an FDA investigational new drug application. Calico aims to advance this asset for age-related diseases, complementing its existing aging biology programs.